Autonomix Medical (NASDAQ:AMIX) Earns Buy Rating from Analysts at Maxim Group

Equities research analysts at Maxim Group assumed coverage on shares of Autonomix Medical (NASDAQ:AMIX) in a research report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $5.00 price target on the stock. Maxim Group’s price target suggests a potential upside of 95.47% from the stock’s previous close.

Autonomix Medical Stock Up 9.3 %

Shares of NASDAQ AMIX opened at $2.56 on Tuesday. The firm has a market cap of $6.30 million, a PE ratio of -0.19 and a beta of -3.08. The business has a 50 day moving average price of $2.07 and a two-hundred day moving average price of $4.55. Autonomix Medical has a fifty-two week low of $1.52 and a fifty-two week high of $75.80.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($1.46) earnings per share (EPS) for the quarter. On average, analysts anticipate that Autonomix Medical will post -10 earnings per share for the current year.

Institutional Trading of Autonomix Medical

A hedge fund recently bought a new stake in Autonomix Medical stock. Citadel Advisors LLC acquired a new stake in Autonomix Medical, Inc. (NASDAQ:AMIX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 47,884 shares of the company’s stock, valued at approximately $180,000. Citadel Advisors LLC owned approximately 4.16% of Autonomix Medical at the end of the most recent reporting period. Institutional investors own 10.78% of the company’s stock.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.